# Sodium–Glucose Cotransporter-2 Inhibitors After Acute Myocardial Infarction

## TL;DR

This paper reviews how SGLT2 inhibitors, originally diabetes drugs, may benefit heart patients after a heart attack by reducing inflammation and improving heart function.

## Contribution

The paper specifically reviews the emerging evidence for SGLT2i use after acute myocardial infarction, focusing on their cardiovascular benefits.

## Key findings

- SGLT2i improve chronic heart failure and reduce rehospitalization due to their diuretic effect.
- SGLT2i may protect against major cardiovascular events and mortality.
- SGLT2i could help post-heart attack recovery by reducing inflammation and ventricular remodeling.

## Abstract

Sodium–glucose cotransporter-2 inhibitors (SGLT2i) are a specific class of drugs originally developed for treating type 2 diabetes mellitus. Subsequently, studies demonstrated that their action was not limited to glycemic control but could also have positive effects on other specific outcomes, particularly at the cardiovascular level. Indeed, due to their diuretic effect, SGLT2i improve the clinical control of chronic heart failure and reduce the risk of rehospitalization. In addition, other studies reported a protective effect on major cardiovascular events and mortality. More recently, it has been suggested that the prescription of SGLT2i after an acute myocardial infarction may have positive effects due to their possible effect on inflammation, arrhythmias, and ventricular remodeling. Here, we reviewed studies focused on SGLT2i after an acute myocardial infarction in patients treated with percutaneous coronary intervention.